GAMMA Investing LLC Raises Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

GAMMA Investing LLC lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 78.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,258 shares of the company’s stock after acquiring an additional 553 shares during the quarter. GAMMA Investing LLC’s holdings in Omnicell were worth $55,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Nisa Investment Advisors LLC increased its stake in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares in the last quarter. EntryPoint Capital LLC increased its stake in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares in the last quarter. CWM LLC raised its holdings in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after acquiring an additional 1,236 shares during the period. Benjamin Edwards Inc. lifted its position in shares of Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after acquiring an additional 868 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Omnicell in the second quarter worth about $104,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OMCL has been the topic of several recent analyst reports. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, October 10th. Benchmark reiterated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company raised their price objective on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.33.

Omnicell Stock Up 0.4 %

Shares of NASDAQ OMCL opened at $42.56 on Thursday. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $45.84. The firm’s 50-day moving average price is $43.19 and its 200-day moving average price is $34.10. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -92.52, a P/E/G ratio of 47.35 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same period last year, the company earned $0.29 EPS. On average, equities research analysts anticipate that Omnicell, Inc. will post 0.64 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.